BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TARPEYO / Nefecon (Budesonide (targeted-release)) readouts · 
 AssetMemo
X-WR-CALDESC:Upcoming readouts of TARPEYO / Nefecon (Budesonide (targeted-r
 elease))\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06528015-910@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:TARPEYO / Nefecon (Budesonide (targeted-release)): Phase 4 readout 
 est. (NCT06528015)
DESCRIPTION:TARPEYO / Nefecon (Budesonide (targeted-release))\, phase 4\, I
 gA Nephropathy.\nStudy: Efficacy and Safety of Probiotics Combined With En
 teric-coated Budesonide Capsules in Patients With Primary IgA Nephropathy\
 nEstimated primary completion: 31 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/budesonide-targeted-release#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06528015
URL:https://assetmemo.bio/drug/budesonide-targeted-release#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07030894-910@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:TARPEYO / Nefecon (Budesonide (targeted-release)): Phase 4 readout 
 est. (NCT07030894)
DESCRIPTION:TARPEYO / Nefecon (Budesonide (targeted-release))\, phase 4\, I
 gA Nephropathy.\nStudy: Nefecon and Ambrisentan in IgA Nephropathy\nEstima
 ted primary completion: 31 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/budesonide-targeted-release#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07030894
URL:https://assetmemo.bio/drug/budesonide-targeted-release#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712407-910@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:TARPEYO / Nefecon (Budesonide (targeted-release)): Phase 4 readout 
 est. (NCT06712407)
DESCRIPTION:TARPEYO / Nefecon (Budesonide (targeted-release))\, phase 4\, I
 gA Nephropathy.\nStudy: Efficacy and Safety of Extended TARPEYO® Treatmen
 t Beyond 9 Months in Adult Patients With Primary IgA Nephropathy\nEstimate
 d primary completion: March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/budesonide-targeted-release#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06712407
URL:https://assetmemo.bio/drug/budesonide-targeted-release#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604311-910@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:TARPEYO / Nefecon (Budesonide (targeted-release)): Phase 4 readout 
 est. (NCT07604311)
DESCRIPTION:TARPEYO / Nefecon (Budesonide (targeted-release))\, phase 4\, I
 gA Nephropathy.\nStudy: Efficacy and Safety of Nefecon on Prevention of Re
 lapse of IgA Nephropathy\nEstimated primary completion: 1 December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/budesonide-targeted-re
 lease#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07604311
URL:https://assetmemo.bio/drug/budesonide-targeted-release#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06676384-910@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:TARPEYO / Nefecon (Budesonide (targeted-release)): Phase 4 readout 
 est. (NCT06676384)
DESCRIPTION:TARPEYO / Nefecon (Budesonide (targeted-release))\, phase 4\, I
 gA Nephropathy.\nStudy: Which of the Commonly Available and Approved Drugs
  in Addition to Standard of Care Can Significantly Improve the Slope of Es
 timated Glomerular Filtration Rate at Two Years When Compared to Standard 
 of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Prim
 ary IgA Nephropathy?\nEstimated primary completion: August 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/budesonide-targeted-release#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT066763
 84
URL:https://assetmemo.bio/drug/budesonide-targeted-release#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
